Hemolytic anemia screening: Difference between revisions
Shyam Patel (talk | contribs) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hemolytic anemia}} | {{Hemolytic anemia}} | ||
{{CMG}} {{shyam}} | {{CMG}}; {{shyam}} | ||
==Overview== | ==Overview== | ||
There is no major role for screening for hemolytic anemia. In some cases, testing for G6PD deficiency can be done if a patient will be receiving medications that are known to | There is no major role for screening for hemolytic anemia. In some cases, testing for G6PD deficiency can be done if a patient will be receiving medications that are known to precipitate oxidative stress. | ||
==Screening== | ==Screening== | ||
Revision as of 18:52, 30 October 2017
|
Hemolytic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemolytic anemia screening On the Web |
|
American Roentgen Ray Society Images of Hemolytic anemia screening |
|
Risk calculators and risk factors for Hemolytic anemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Shyam Patel [2]
Overview
There is no major role for screening for hemolytic anemia. In some cases, testing for G6PD deficiency can be done if a patient will be receiving medications that are known to precipitate oxidative stress.
Screening
In some cases, screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. Primaquine, sulfa drugs, and fava beans can trigger hemolytic crises in the setting of G6PD deficiency.[1] Rasburicase has also been shown to trigger hemolytic episodes, so G6PD screening is important prior to administration of rasburicase.[1]
References
- ↑ 1.0 1.1 Luzzatto L, Seneca E (2014). "G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications". Br J Haematol. 164 (4): 469–80. doi:10.1111/bjh.12665. PMC 4153881. PMID 24372186.